AR047163A1 - Derivados de ciclohexano espirociclicos con afinidad por el receptor orl1 - Google Patents
Derivados de ciclohexano espirociclicos con afinidad por el receptor orl1Info
- Publication number
- AR047163A1 AR047163A1 ARP040104857A ARP040104857A AR047163A1 AR 047163 A1 AR047163 A1 AR 047163A1 AR P040104857 A ARP040104857 A AR P040104857A AR P040104857 A ARP040104857 A AR P040104857A AR 047163 A1 AR047163 A1 AR 047163A1
- Authority
- AR
- Argentina
- Prior art keywords
- unsubstituted
- multiplely
- substituted individually
- heteroaryl
- aryl
- Prior art date
Links
- 125000001072 heteroaryl group Chemical group 0.000 abstract 19
- 125000003118 aryl group Chemical group 0.000 abstract 17
- 229920006395 saturated elastomer Polymers 0.000 abstract 17
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 16
- 125000000217 alkyl group Chemical group 0.000 abstract 12
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 9
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical class [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Métodos de preparacion, composiciones farmacéuticas que los contienen, y usos. Reivindicacion 1: Derivados de ciclohexano espirocíclicos de la siguiente formula general (1), caracterizado porque: R1 y R2 representan en forma independiente entre sí: H, CHO; alquilo C1-5 respectivamente saturado o no saturado, ramificado o no ramificado, sustituido en forma individual o multiple o no sustituido; cicloalquilo C3-8 respectivamente saturado o no saturado, sustituido en forma individual o multiple o no sustituido; o arilo, cicloalquilo C3-8 o heteroarilo unido por alquilo C1-3; respectivamente sustituido en forma individual o multiple o no sustituido; o los radicales R1 y R2 representan juntos CH2CH2OCH2CH2, CH2CH2NR11CH2CH2 o (CH2)3-6, donde R11 representa H; alquilo C1-5 respectivamente saturado o no saturado, ramificado o no ramificado, sustituido en forma individual o multiple o no sustituido; cicloalquilo C3-8 respectivamente saturado o no saturado, sustituido en forma individual o multiple o no sustituido; arilo o heteroarilo respectivamente sustituido en forma individual o multiple o no sustituido; o arilo, cicloalquilo C3-8 o heteroarilo unido por alquilo C1-3, respectivamente sustituido en forma individual o multiple o no sustituido; R3 representa heteroarilo o heteroarilo C1-3 respectivamente sustituido en forma individual o multiple; W representa NR4, O o S; y R4 representa H; alquilo C1-5 saturado o no saturado, ramificado o no ramificado, no sustituido o sustituido en forma individual o multiple; arilo, o heteroarilo respectivamente sustituido o no sustituido; arilo, heteroarilo o cicloalquilo unido por grupo alquilo C1-3, respectivamente sustituido en forma individual o multiple o no sustituido; COR12; SO2R12, donde R12 representa H; alquilo C1-5 respectivamente saturado o no saturado, ramificado o no ramificado, sustituido en forma individual o multiple o no sustituido; cicloalquilo C3-8 respectivamente saturado o no saturado, sustituido en forma individual o multiple o no sustituido; arilo o heteroarilo respectivamente sustituido en forma individual o multiple o no sustituido; o arilo, cicloalquilo C3-8 o heteroarilo unido por alquilo C1-3, respectivamente sustituido en forma individual o multiple o no sustituido; OR13, NR14R15; R5 presenta =O, H; COOR13, CONR13, OR13; alquilo C1-5 saturado o no saturado, ramificado o no ramificado, no sustituido o sustituido en forma individual o multiple; cicloalquilo C3-8 saturado o no saturado, no sustituido o sustituido en forma individual o multiple; arilo o heteroarilo no sustituido o sustituido en forma individual o multiple; o arilo, cicloalquilo C3-8 o heteroarilo unido por alquilo C1-3, no sustituido o sustituido en forma individual o multiple; multiple; R6 representa H; F; Cl, NO2, CF3, OR13, SR13, SO2R13, SO2OR13, CN, COOR13, NR14R15; alquilo C1-5 saturado o no saturado, ramificado o no ramificado, no sustituido o sustituido en forma individual o multiple; cicloalquilo C3-8 saturado o no saturado, no sustituido o sustituido en forma individual o multiple; arilo o heteroarilo, no sustituido o sustituido en forma individual o multiple; o arilo, cicloalquilo C3-8 o heteroarilo unido por alquilo C1-3, no sustituido o sustituido en forma individual o multiple; o R5 y R6 representan juntos (CH2)n con n = 2, 3, 4, 5 o 6, donde átomos de hidrogeno individuales pueden estar reemplazados también por F, Cl, Br, I, NO2, CF3, OR13, CN o alquilo C1-5; R7, R8, R9 y R10 representan en forma independiente entre sí H, F, Cl, Br, I, NO2, CF3, OR13, SR13, SO2R13, SO2OR13, CN, COOR13, NR14R15; alquilo C1-5, cicloalquilo C3-8, no sustituido o sustituido en forma individual o multiple; arilo o heteroarilo no sustituido o sustituido en forma individual o multiple; o arilo, cicloalquilo C3-8 o heteroarilo unido por alquilo C1-3, no sustituido o sustituido en forma individual o multiple; donde R13 representa H; alquilo C1-5 respectivamente saturado o no saturado, ramificado o no ramificado, no sustituido o sustituido en forma individual o multiple; cicloalquilo C3-8 respectivamente saturado o no saturado, no sustituido o sustituido en forma individual o multiple; arilo o heteroarilo no sustituido o sustituido en forma individual o multiple; o arilo, cicloalquilo C3-8 o heteroarilo unido por alquilo C1-3, no sustituido o sustituido en forma individual o multiple; R14 y R15 representan en forma independiente entre sí H; alquilo C1-5 respectivamente saturado o no saturado, ramificado o no ramificado, no sustituido o sustituido en forma individual o multiple; o cicloalquilo C3-8 respectivamente saturado o no saturado, no sustituido o sustituido en forma individual o multiple; arilo o heteroarilo no sustituido o sustituido en forma individual o multiple; o arilo, cicloalquilo C3-8 o heteroarilo unido por alquilo C1-3, no sustituido o sustituido en forma individual o multiple; o R14 y R15 forman juntos CH2CH2OCH2CH2, CH2CH2NR16CH2CH2 o (CH2)3-6, donde R16 representa H; alquilo C1-5 saturado o no saturado, ramificado o no ramificado, no sustituido o sustituido en forma individual o multiple; X representa O, S, SO, SO2 o NR17; R17 representa H, alquilo C1-5, saturado o no saturado, ramificado o no ramificado; COR12 o SO2R12, en la forma del racemato; de los enantiomeros, diastereomeros, mezclas de los enantiomeros o diastereomeros o de un enantiomero o diastereomero individual; de las bases y/o sales de ácido o cationes fisiologicamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10360792A DE10360792A1 (de) | 2003-12-23 | 2003-12-23 | Spirocyclische Cyclohexan-Derivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR047163A1 true AR047163A1 (es) | 2006-01-11 |
Family
ID=34706497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040104857A AR047163A1 (es) | 2003-12-23 | 2004-12-22 | Derivados de ciclohexano espirociclicos con afinidad por el receptor orl1 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7332519B2 (es) |
| EP (1) | EP1725567B1 (es) |
| JP (1) | JP4885733B2 (es) |
| KR (1) | KR101152693B1 (es) |
| CN (1) | CN1922189B (es) |
| AR (1) | AR047163A1 (es) |
| AT (1) | ATE390430T1 (es) |
| AU (1) | AU2004312147B2 (es) |
| BR (1) | BRPI0418052A2 (es) |
| CA (1) | CA2550868C (es) |
| CY (1) | CY1107975T1 (es) |
| DE (2) | DE10360792A1 (es) |
| DK (1) | DK1725567T3 (es) |
| EC (1) | ECSP066667A (es) |
| ES (1) | ES2303964T3 (es) |
| HR (1) | HRP20080272T3 (es) |
| IL (1) | IL176457A (es) |
| MX (1) | MXPA06007171A (es) |
| NO (1) | NO337127B1 (es) |
| NZ (1) | NZ548317A (es) |
| PE (1) | PE20050758A1 (es) |
| PL (1) | PL1725567T3 (es) |
| PT (1) | PT1725567E (es) |
| RU (1) | RU2383544C2 (es) |
| SI (1) | SI1725567T1 (es) |
| WO (1) | WO2005066183A1 (es) |
| ZA (1) | ZA200606067B (es) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| DE10252667A1 (de) | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102004032051A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
| DE10360793A1 (de) * | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102005016460A1 (de) | 2005-04-11 | 2006-10-19 | Grünenthal GmbH | Spriocyclische Cyclohexanderivate zur Behandlung von Substanzabhängigkeit |
| DE102006019597A1 (de) | 2006-04-27 | 2007-10-31 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| DE102006033114A1 (de) | 2006-07-18 | 2008-01-24 | Grünenthal GmbH | Spirocyclische Azaindol-Derivate |
| EP1894938A1 (en) * | 2006-08-31 | 2008-03-05 | Evonik Degussa GmbH | New cyclopentadienyl, indenyl or fluorenyl substituted phosphine compounds and their use in catalytic reactions |
| DE102006046745A1 (de) * | 2006-09-29 | 2008-04-03 | Grünenthal GmbH | Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz |
| DE102007009235A1 (de) | 2007-02-22 | 2008-09-18 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| DE102007009319A1 (de) | 2007-02-22 | 2008-08-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
| JP5501251B2 (ja) * | 2008-01-11 | 2014-05-21 | アルバニー モレキュラー リサーチ， インコーポレイテッド | Ｍｃｈ拮抗薬としての（１−アジノン）置換ピリドインドール類 |
| MX2010008138A (es) | 2008-01-25 | 2010-08-10 | Gruenenthal Gmbh | Forma de dosis farmaceutica. |
| AU2009228642B2 (en) | 2008-03-27 | 2013-11-07 | Grunenthal Gmbh | Substituted 4-aminocyclohexane derivatives |
| ES2375543T3 (es) * | 2008-03-27 | 2012-03-01 | Grünenthal GmbH | Derivados de espiro(5.5)undecano. |
| JP5650637B2 (ja) | 2008-03-27 | 2015-01-07 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | （ヘテロ−）アリール−シクロヘキサン誘導体 |
| CN102046596B (zh) | 2008-03-27 | 2013-12-25 | 格吕伦塔尔有限公司 | 取代的环己二胺 |
| AU2009228647B2 (en) * | 2008-03-27 | 2013-07-04 | Grunenthal Gmbh | Substituted spirocyclic cyclohexane derivatives |
| RU2514192C2 (ru) * | 2008-03-27 | 2014-04-27 | Грюненталь Гмбх | Гидроксиметилциклогексиламины |
| TWI524904B (zh) | 2008-05-09 | 2016-03-11 | 歌林達股份有限公司 | 製備醫藥用固體劑型，尤指錠劑之方法，及製備固體劑型，尤指錠劑之前驅物之方法 |
| HRP20121060T1 (hr) | 2008-11-13 | 2013-01-31 | F. Hoffmann - La Roche Ag | Spiro-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo[e]azuleni |
| WO2011003012A1 (en) * | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof |
| WO2011003021A1 (en) * | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof |
| EP2448585B1 (en) * | 2009-07-01 | 2014-01-01 | Albany Molecular Research, Inc. | Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof |
| WO2011003007A1 (en) * | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof |
| EP2456425B1 (en) | 2009-07-22 | 2015-10-21 | Grünenthal GmbH | Tamper-resistant dosage form for oxidation-sensitive opioids |
| CA2765971C (en) | 2009-07-22 | 2017-08-22 | Gruenenthal Gmbh | Hot-melt extruded controlled release dosage form |
| EP2501704B1 (en) * | 2009-11-16 | 2013-09-18 | Eli Lilly and Company | Spiropiperidine compounds as oral-1 receptor antagagonisten |
| UA107943C2 (xx) * | 2009-11-16 | 2015-03-10 | Lilly Co Eli | Сполуки спіропіперидину як антагоністи рецептора orl-1 |
| AU2011269429B2 (en) * | 2010-06-24 | 2015-07-09 | UNION therapeutics A/S | Benzodioxole or benzodioxepine heterocyclic compounds phosphodiesterase inhibitors |
| TWI582092B (zh) * | 2010-07-28 | 2017-05-11 | 歌林達股份有限公司 | 順式－四氫－螺旋（環己烷－１,１’－吡啶［３,４－b］吲哚）－４－胺－衍生物 |
| KR20130137627A (ko) | 2010-09-02 | 2013-12-17 | 그뤼넨탈 게엠베하 | 음이온성 중합체를 포함하는 내변조성 투여형 |
| CN103179956A (zh) | 2010-09-02 | 2013-06-26 | 格吕伦塔尔有限公司 | 包含阴离子聚合物的抗破碎剂型 |
| EP2611426B1 (en) | 2010-09-02 | 2014-06-25 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
| WO2012088038A2 (en) | 2010-12-21 | 2012-06-28 | Albany Molecular Research, Inc. | Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof |
| US8993765B2 (en) | 2010-12-21 | 2015-03-31 | Albany Molecular Research, Inc. | Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof |
| CN103857386A (zh) | 2011-07-29 | 2014-06-11 | 格吕伦塔尔有限公司 | 提供药物立即释放的抗破碎片剂 |
| KR20140053159A (ko) | 2011-07-29 | 2014-05-07 | 그뤼넨탈 게엠베하 | 즉시 약물 방출을 제공하는 탬퍼-저항성 정제 |
| PL2809320T3 (pl) * | 2012-02-03 | 2017-09-29 | Grünenthal GmbH | (1R,4R)-6'-fluoro-(N-metylo- lub N,N-dimetylo-)-4-fenylo-4',9'-dihydro-3'H-spiro-[cykloheksano-1,1'-pirano[3,4,b]indolo]-4-amina do leczenia fibromialgii i zespołu przewlekłego zmęczenia |
| US20130225625A1 (en) | 2012-02-28 | 2013-08-29 | Grunenthal Gmbh | Tamper-resistant pharmaceutical dosage form comprising nonionic surfactant |
| EP2819656A1 (en) | 2012-02-28 | 2015-01-07 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
| PT2838512T (pt) | 2012-04-18 | 2018-11-09 | Gruenenthal Gmbh | Forma farmacêutica resistente à adulteração e resistente à libertação inesperada de alta quantidade (dose-dumping) |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| EA029171B1 (ru) | 2012-05-11 | 2018-02-28 | Грюненталь Гмбх | Термоформованная устойчивая к разрушению фармацевтическая лекарственная форма, содержащая цинк, и способ ее получения |
| US20130310435A1 (en) * | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol |
| US9320725B2 (en) * | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid |
| US9855286B2 (en) * | 2012-05-18 | 2018-01-02 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component |
| US8912226B2 (en) * | 2012-05-18 | 2014-12-16 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR |
| US9345689B2 (en) * | 2012-05-18 | 2016-05-24 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant |
| US9320729B2 (en) * | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative |
| US20130310385A1 (en) * | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants |
| US9308196B2 (en) * | 2012-05-18 | 2016-04-12 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam |
| EP2970284B1 (en) | 2013-03-15 | 2017-11-01 | Grünenthal GmbH | Crystalline cis-(e)-4-(3-fluorophenyl)-2',3',4',9'-tetrahydro-n,n-dimethyl-2'-(1-oxo-3-phenyl-2-propenyl)-spiro[cyclohexane-1,1'[1h]-pyrido[3,4-b]indol]-4-amine |
| AU2014273227B2 (en) | 2013-05-29 | 2019-08-15 | Grunenthal Gmbh | Tamper-resistant dosage form containing one or more particles |
| AU2014273226B2 (en) | 2013-05-29 | 2019-06-27 | Grunenthal Gmbh | Tamper resistant dosage form with bimodal release profile |
| EP3019157A1 (en) | 2013-07-12 | 2016-05-18 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
| CN105934241B (zh) | 2013-11-26 | 2020-06-05 | 格吕伦塔尔有限公司 | 通过低温研磨制备粉末状药物组合物 |
| WO2015091352A1 (en) | 2013-12-16 | 2015-06-25 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile manufactured by co-extrusion |
| CN106572980A (zh) | 2014-05-12 | 2017-04-19 | 格吕伦塔尔有限公司 | 包含他喷他多的防篡改即释胶囊制剂 |
| MX2016015417A (es) | 2014-05-26 | 2017-02-22 | Gruenenthal Gmbh | Multiparticulas protegidas contra vertido de dosis etanolico. |
| TW201607923A (zh) | 2014-07-15 | 2016-03-01 | 歌林達有限公司 | 被取代之氮螺環（４．５）癸烷衍生物 |
| US10214520B2 (en) | 2014-07-15 | 2019-02-26 | Gruenenthal Gmbh | Substituted azaspiro(4.5)decane derivatives |
| CA2975653A1 (en) | 2015-02-03 | 2016-08-11 | Grunenthal Gmbh | Tamper-resistant dosage form comprising a polyethylene glycol graft copolymer |
| US20160310429A1 (en) | 2015-04-24 | 2016-10-27 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| AU2016319203A1 (en) | 2015-09-10 | 2018-02-22 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
| JP7195141B2 (ja) | 2015-10-22 | 2022-12-23 | ジュノ セラピューティクス ゲーエムベーハー | 形質導入のための方法、キット、作用物質および装置 |
| WO2018007507A1 (en) | 2016-07-06 | 2018-01-11 | Grünenthal GmbH | Reinforced pharmaceutical dosage form |
| GB202306662D0 (en) | 2023-05-05 | 2023-06-21 | Union Therapeutics As | Dosage regimen |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3843681A (en) * | 1971-06-01 | 1974-10-22 | American Home Prod | 1-carboxamido pyrano(thiopyrano)(3,4-6)indole derivatives |
| FR2663935A1 (fr) * | 1990-06-27 | 1992-01-03 | Adir | Nouveaux 1,2,3,4,5,6-hexahydroazepino [4,5-b] indoles et 1,2,3,4-tetrahydrobethacarbolines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. |
| IL140197A0 (en) * | 1998-06-12 | 2002-02-10 | Sod Conseils Rech Applic | β-CARBOLINE COMPOUNDS |
| WO2000038720A1 (en) * | 1998-12-24 | 2000-07-06 | Meiji Seika Kaisha, Ltd. | Remedies for pain |
| DE10044649A1 (de) * | 2000-09-08 | 2002-07-04 | Gruenenthal Gmbh | Substituierte 4-Phenyl-1-(1-phenyl-cyclohexyl)-1,2,3,6-tetrahydropyridine |
| DE10123163A1 (de) * | 2001-05-09 | 2003-01-16 | Gruenenthal Gmbh | Substituierte Cyclohexan-1,4-diaminderivate |
| DE10252667A1 (de) * | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| DE10360793A1 (de) * | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
-
2003
- 2003-12-23 DE DE10360792A patent/DE10360792A1/de not_active Withdrawn
-
2004
- 2004-12-21 ES ES04804136T patent/ES2303964T3/es not_active Expired - Lifetime
- 2004-12-21 PT PT04804136T patent/PT1725567E/pt unknown
- 2004-12-21 AU AU2004312147A patent/AU2004312147B2/en not_active Ceased
- 2004-12-21 PL PL04804136T patent/PL1725567T3/pl unknown
- 2004-12-21 DK DK04804136T patent/DK1725567T3/da active
- 2004-12-21 KR KR1020067014815A patent/KR101152693B1/ko not_active Expired - Fee Related
- 2004-12-21 EP EP04804136A patent/EP1725567B1/de not_active Expired - Lifetime
- 2004-12-21 RU RU2006126787/04A patent/RU2383544C2/ru not_active IP Right Cessation
- 2004-12-21 NZ NZ548317A patent/NZ548317A/en not_active IP Right Cessation
- 2004-12-21 SI SI200430663T patent/SI1725567T1/sl unknown
- 2004-12-21 CA CA2550868A patent/CA2550868C/en not_active Expired - Fee Related
- 2004-12-21 BR BRPI0418052A patent/BRPI0418052A2/pt not_active Application Discontinuation
- 2004-12-21 DE DE502004006697T patent/DE502004006697D1/de not_active Expired - Lifetime
- 2004-12-21 MX MXPA06007171A patent/MXPA06007171A/es active IP Right Grant
- 2004-12-21 JP JP2006546040A patent/JP4885733B2/ja not_active Expired - Fee Related
- 2004-12-21 AT AT04804136T patent/ATE390430T1/de active
- 2004-12-21 HR HR20080272T patent/HRP20080272T3/xx unknown
- 2004-12-21 CN CN2004800420360A patent/CN1922189B/zh not_active Expired - Fee Related
- 2004-12-21 WO PCT/EP2004/014539 patent/WO2005066183A1/de not_active Ceased
- 2004-12-22 AR ARP040104857A patent/AR047163A1/es not_active Application Discontinuation
- 2004-12-23 US US11/019,372 patent/US7332519B2/en not_active Expired - Fee Related
-
2005
- 2005-01-03 PE PE2005000023A patent/PE20050758A1/es not_active Application Discontinuation
-
2006
- 2006-06-21 EC EC2006006667A patent/ECSP066667A/es unknown
- 2006-06-21 IL IL176457A patent/IL176457A/en not_active IP Right Cessation
- 2006-07-21 ZA ZA200606067A patent/ZA200606067B/en unknown
- 2006-07-24 NO NO20063422A patent/NO337127B1/no not_active IP Right Cessation
-
2008
- 2008-05-29 CY CY20081100557T patent/CY1107975T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR047163A1 (es) | Derivados de ciclohexano espirociclicos con afinidad por el receptor orl1 | |
| AR074529A2 (es) | Derivados de ciclohexano espirociclicos | |
| AR062079A1 (es) | Derivados de azaindol sustituidos, procedimientos para su preparacion, composiciones farmaceuticas que contienen estos compuestos y el uso de derivados de azaindol sustituidos para la preparacion de composiciones farmaceuticas | |
| AR046794A1 (es) | Derivados de ciclohexano espirociclicos, un metodo para su preparacion y medicamentos que los contienen como principio activo. | |
| AR041941A1 (es) | Derivado de 1-aminociclohexano sustituidos en la posicion 4 utilizado como receptor orl1 | |
| AR035883A1 (es) | Derivados de ciclohexano-1,4-diamina sustituidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y su uso para la preparacion de medicamentos | |
| ECSP034475A (es) | Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1 | |
| AR037489A1 (es) | Quinolinas sustituidas y proceso para su preparacion | |
| AR038047A1 (es) | Agentes terapeuticos | |
| AR034283A1 (es) | Compuestos heterociclilindazol y azaindazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
| AR070398A1 (es) | Derivados sustituidos de indol | |
| AR070187A1 (es) | Derivados de dulfonamidas sustituidas | |
| AR062680A1 (es) | Sintesis de 2-(piridin-2-ilamino) pirido [2,3-d] pirimidin-7-onas | |
| CO5580820A2 (es) | Derivados novedosos de acido (2s)-3-(4-{2-[amino]-2-oxoetoxi} fenil)-2-etoxipropanoico procesos para su preparacion y composiciones farmaceuticas que los contienen | |
| AR050261A2 (es) | Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento | |
| AR075249A1 (es) | Derivados de 6-(6-o-sustituido-triazolopiridazina-sulfanil) benzotiazoles y bencimidazoles, metodo de preparacion de los mismos e intermediarios de dicha sintesis, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer, artritis, alergias y otras enfermedades. | |
| AR070910A1 (es) | Derivados de sulfonamida sustituida | |
| AR048607A1 (es) | Derivados (poli)aminoalquilaminoacetamida de la epipodofilotoxina, proceso de preparacion de los mismos y sus aplicaciones terapeuticas como agentes anticancerosos | |
| AR043427A1 (es) | Derivados de acido alcanoico sustituidos con aril-cicloalquilo, procedimientos para su obtencion, y su empleo como medicamentos | |
| AR054783A1 (es) | Derivados de pirrolo-quinolinas moduladores selectivos de receptores de androgeno | |
| AR030239A1 (es) | Fta lidas substituidas, un procedimiento para su preparacion y composiciones farmaceuticas que contienen las mismas | |
| AR060086A1 (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos | |
| CR9499A (es) | Nuevos derivados de fenilpiridinilpiperazina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR072336A1 (es) | Derivados de la 3-carboxipropil-aminotetralina, composiciones farmaceuticas que los contienen, procedimiento para su preparacion, intermediarios y su procedimiento de preparacion | |
| PE20020426A1 (es) | ß-TIO-a-AMINOACIDOS, PROCEDIMIENTOS PARA SU PREPARACION Y MEDICAMENTOS QUE LOS CONTIENEN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed, e.g., due to non-payment of fee |